Related Experiment Video
Updated: Feb 23, 2026
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Comparison of 3 Predictive Clinical Risk Scores in 603 Patients with Stable Coronary Artery Disease
Insights
Different clinical risk scores show varying accuracy in predicting coronary artery disease outcomes. The Framingham score best predicted thrombotic events, while LIPID and VILCAD scores were better for heart failure or death.
Area of Science:
- Cardiology
- Clinical Risk Assessment
- Predictive Modeling
Background:
- No single clinical risk score is universally accepted for coronary artery disease (CAD).
- Existing risk scores may have variable predictive power for different CAD outcomes.
- Accurate risk stratification is crucial for managing patients with stable CAD.
Purpose of the Study:
- To investigate and compare the predictive power of established clinical risk scores for various outcomes in patients with stable coronary artery disease.
- To evaluate the performance of Framingham, Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), and Vienna and Ludwigshafen Coronary Artery Disease (VILCAD) scores.
- To assess the accuracy of these scores in predicting acute thrombotic events, heart failure or death, and a combined primary outcome.
Main Methods:
- A cohort of 603 patients with stable coronary artery disease was followed over approximately 2 years.
- The predictive accuracy of Framingham, LIPID, and VILCAD risk scores was assessed.
- Outcomes included acute thrombotic events, heart failure or death, and a composite primary outcome.
- Statistical analyses included hazard ratios (HR) and net reclassification index (NRI) to evaluate predictive improvement.
Main Results:
- The Framingham score significantly predicted acute thrombotic events (HR=1.05, P=0.03) with a notable NRI of 9.7%.
- Both LIPID (HR=1.13, P=0.005) and VILCAD (HR=1.99, P<0.001) scores effectively predicted heart failure or death, with VILCAD showing a higher NRI (18.6%).
- The LIPID (HR=1.1, P=0.005) and VILCAD (HR=1.39, P=0.003) scores also predicted the primary composite outcome, with VILCAD demonstrating a substantial NRI of 19.4%.
Conclusions:
- The predictive accuracy of clinical risk scores for coronary artery disease varies depending on the specific outcome being assessed.
- The Framingham score demonstrated utility in predicting thrombotic events.
- LIPID and VILCAD scores showed stronger predictive capabilities for adverse events like heart failure, death, or the composite outcome, with VILCAD being particularly effective.
Abstract:
No clinical risk score is universally accepted for coronary artery disease. In 603 patients (mean age, 61.2 ± 12.3 yr) with stable coronary artery disease, we investigated the predictive power of clinical risk scores derived from the Framingham, the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), and the Vienna and Ludwigshafen Coronary Artery Disease (VILCAD) studies. Secondary outcomes were the recurrence of an acute thrombotic event (coronary events, strokes, or transient ischemic attacks), or heart failure or death. The primary outcome was the combination of secondary outcomes. During follow-up (duration, 2.08 ± 0.97 yr), 42 patients had an acute thrombotic event; 22, heart failure or death; and 60, the primary outcome. The Framingham score predicted acute thrombotic events: hazard ratio (HR)=1.05; 95% confidence interval (CI), 1.01-1.08; P=0.03; net reclassification index (NRI, calculated to evaluate improvement in prediction gained by adding different risk scores to models constructed with variables excluded from the calculation of that score)=9.7% (95% CI, 9.6-9.8). The LIPID (HR=1.13; 95% CI, 1.04-1.22; P=0.005) and VILCAD scores (HR=1.99; 95% CI, 1.48-2.67; P <0.001) predicted heart failure or death with NRIs of 5.8% (95% CI, 5.7-5.9) and 18.6% (95% CI, 18.3-18.9), respectively. The primary outcome was predicted by the LIPID (HR=1.1; 95% CI, 1.03-1.17; P=0.005) and VILCAD scores (HR=1.39; 95% CI, 1.13-1.70; P=0.003). The NRIs (95% CIs) were 3.4% (3.3-3.5) and 19.4% (19.3-19.6), respectively. We conclude that the accuracy of these risk scores varies in accordance with the outcome studied.
More Related Videos
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Related Concept Videos
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Coronary Artery Disease III: Clinical Manifestations
01:27Coronary Artery Disease V: Interprofessional Care
01:12Relative Risk
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...